Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Rona Therapeutics In-licenses Exclusive Global Rights to Sanofi’s siRNA Platform

publication date: Jul 25, 2022

Shanghai Rona Therapeutics, an RNA company, acquired worldwide exclusive rights to Sanofi’s siRNA platform of chemical modification and delivery moiety plus rights to four pre-clinical candidates for liver diseases. Sanofi will have an option to in-license selected neuro and muscular candidates for territories outside Greater China that Rona discovers using the siRNA platform. Rona will make upfront and milestone payments to Sanofi plus royalties, though the amounts were not disclosed. Rona said the deal will expand its siRNA portfolio in liver and non-liver applications. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital